Wednesday June 11

June 11, 2024

Movers

Ipsen (Euronext: IPN) announced that Iqirvo® (elafibranor) 80 mg tablets have received U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC). (LINK)
The Senate Committee on Health, Education, Labor, and Pensions will vote during a meeting on June 18 to subpoena Novo Nordisk (NYSE: NVO) President Doug Langa regarding the high prices of its GLP-1 drugs Ozempic and Wegovy.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for polyarticular juvenile idiopathic arthritis (pJIA), a form of arthritis that impacts multiple joints. (LINK)
Regeneron (NASDAQ: REGN) won a permanent injunction blocking drugmakers from launching a generic version of its blockbuster eye drug Eylea
Johnson & Johnson (NYSE: JNJ) has reached a $700 million settlement with 43 state attorneys general over the company's marketing of baby powder products containing talc

Processa Pharmaceuticals (NASDAQ: PCSA) announced positive efficacy results from the preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Capecitabine in gastrointestinal cancer. (LINK)
Annovis Bio (NYSE: ANVS) announced statistically significant Phase II/III data in patients with early Alzheimer's disease. (LINK)

Moleculent, a Stockholm, Sweden-based provider of a functional biology platform, raised $26 million in Series A funding. The round was co-led by ARCH Venture Partners and Eir Ventures, with participation from existing investors. (LINK)
Bright Peak Therapeutics announced that it raised $90 million in a Series C financing led by Johnson & Johnson Innovation – JJDC, with participation from new investors Venrock, KB Investment, and Northleaf Capital Partners. (LINK)

Aerovate Therapeutics (NASDAQ: AVTE) filed a prospectus for the sale of $350 million in mixed securities. (LINK)

(AZN) Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. (LINK)Mutated NSCLC

Reeling from an FDA setback, researchers are plotting the future of psychedelic-assisted medicine. (LINK)
Stage III EGFR-Mutated NSCLC